Healthcare / Medical DevicesNYSE American
$0.96
+0.04 (+4.04%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-9.3M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$3M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-243.6%
↓Gross Margin
92.3%
↑Debt/Equity
0.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
-21.8%
FCF CAGR
—
FCF margin
-1029.2%
FCF / Net income
0.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $819000.0 · net income $-17.2M · FCF $-8.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $819000.00 | $819000.00 | $420000.00 | $442000.00 | $14000.00 | $22000.00 | $259000.00 | $7.2M | $6.3M | $5.9M |
| Net Income | $-17.2M | $-17.2M | $-16.6M | $-70.6M | $-26.9M | $-25.1M | $-36.0M | $-57.0M | $-30.8M | $-17.8M |
| EBITDA | $-17.1M | $-17.1M | $-11.3M | $-68.5M | $-22.4M | $-27.7M | $-33.0M | $-56.0M | — | — |
| EPS | -15.90 | -15.90 | -126.91 | -2467.72 | -4936.20 | -47161.80 | — | — | — | — |
| Gross Margin | 92.3% | 92.3% | 90.0% | 93.2% | -1050.0% | -6990.9% | -738.6% | -22.9% | 32.8% | 29.0% |
| Operating Margin | -1487.3% | -1487.3% | -2676.9% | -3888.0% | -162778.6% | -133027.3% | -13668.3% | -801.9% | -498.0% | -302.6% |
| Net Margin | -2098.0% | -2098.0% | -3962.6% | -15966.5% | -191892.9% | -113954.5% | -13917.0% | -791.2% | -492.8% | -302.6% |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.55 | 0.55 | 0.16 | 0.02 | — | — | — | 0.02 | 0.01 | — |
| Current Ratio | 0.06 | 0.06 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-8.4M | $-8.4M | $-9.3M | $-20.7M | $-22.6M | $-27.9M | $-28.4M | $-33.4M | $-19.1M | $-6.1M |
| Returns | ||||||||||
| ROE | -243.6% | -243.6% | -141.6% | -333.0% | -290.1% | -183.4% | -170.4% | -171.8% | -46.2% | 233.3% |
| Valuation | ||||||||||
| P/B | 0.15 | 0.15 | 0.15 | 0.10 | 0.72 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 95.0% | 95.0% | -5.0% | 3057.1% | — | -91.5% | -96.4% | 15.1% | 6.6% | — |
| EPS Growth | 87.5% | 87.5% | 94.9% | 50.0% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-73.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-126.91 → -15.90
Residual
-73.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.